Repatha (evolocumab) lowered the risk of death from any cause by 20% in high-risk adults without a previous heart attack or ...
The FDA has approved Lilly’s Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack, or non-fatal stroke in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results